Mechanical thrombectomy in intermediate-high-risk pulmonary embolism: STORM-PE trial results show improved 6-minute walk distance and functional recovery

Management of intermediate-high-risk pulmonary embolism (PE) remains one of the most debated areas in contemporary cardiovascular care. While anticoagulation remains foundational therapy, the question has long been whether earlier catheter-based reperfusion can meaningfully improve not just surrogate markers—but how patients actually feel and function.

The interim functional outcomes from the STORM-PE trial move the field closer to that answer.

---

From RV/LV Ratios to Real-World Functional Recovery

The primary results of STORM-PE demonstrated that computer-assisted vacuum thrombectomy (CAVT) plus anticoagulation led to significantly greater reduction in RV/LV ratio at 48 hours compared with anticoagulation alone.

However, imaging metrics alone rarely drive bedside decisions.

What makes the 90-day data compelling is the shift toward patient-centered functional outcomes:

• 6-minute walk distance was significantly greater in the thrombectomy arm (479 m vs 368 m).
• NYHA Class I status was achieved in 97% vs 76%.
• A higher proportion returned to predicted baseline functional capacity.

Earlier right ventricular stabilization appears to translate into improved exercise tolerance, reduced dyspnea burden, and faster return to daily activity.

---

Context: Evolving Evidence in Intermediate-Risk PE

Historically, guidelines recommended anticoagulation alone for most intermediate-risk PE patients, reserving advanced therapies for clinical deterioration.

The 2026 AHA/ACC/ACCP PE Guidelines reflect this evolving landscape. Mechanical thrombectomy carries:

• Class 2a recommendation in high-risk PE
• Class 2b recommendation in select intermediate-high-risk patients when advanced therapy is being considered

Recent randomized data are reshaping this conversation:

• PEERLESS Trial (2025) demonstrated that large-bore mechanical thrombectomy reduced clinical deterioration and ICU utilization compared with catheter-directed thrombolysis, with similar mortality and bleeding rates.
• Contemporary registry data from the PERT Consortium (JACC 2026) show rapid national adoption of mechanical thrombectomy, particularly in higher-acuity patients.

STORM-PE extends this trajectory by suggesting benefits beyond early hemodynamic improvement—toward functional recovery and quality of life.

---

Why Functional Outcomes Matter

Up to 40–50% of PE survivors experience some degree of exercise limitation, persistent dyspnea, or features of post-PE syndrome, even after adequate anticoagulation.

If early thrombus removal:

• Reduces RV strain
• Preserves cardiopulmonary reserve
• Improves 6-minute walk performance
• Accelerates return to baseline activity

Then we may be shifting the goal from merely preventing mortality to improving long-term functional capacity and quality of life.

Mortality differences in intermediate-risk PE remain difficult to demonstrate. But for many patients, being able to walk normally, breathe comfortably, and resume daily activities is a highly meaningful endpoint.

---

The Emerging Treatment Paradigm

We are witnessing a transition from purely anatomy- and biomarker-driven decision-making toward a model that incorporates:

• Hemodynamic stabilization
• Functional recovery
• Quality-of-life outcomes
• Multidisciplinary PERT-based evaluation

STORM-PE does not close the book on optimal management of intermediate-high-risk PE. But it adds important evidence that mechanical thrombectomy may improve how patients recover—not just how their scans look.

For cardiologists involved in acute PE response teams, these data are likely to influence discussions with referring physicians and patients in 2026 and beyond.

---

References

1. STORM-PE Trial. Randomized controlled trial of mechanical thrombectomy plus anticoagulation vs anticoagulation alone in intermediate-high-risk PE. Circulation. 2026.

2. 2026 AHA/ACC/ACCP Guideline for the Evaluation and Management of Acute Pulmonary Embolism. Circulation. 2026.

3. PEERLESS Trial. Large-bore mechanical thrombectomy vs catheter-directed thrombolysis in intermediate-risk PE. Circulation. 2025.

4. PERT Consortium Registry (2016–2024). Trends in mechanical thrombectomy and catheter-directed therapies for acute PE. J Am Coll Cardiol. 2026.

5. Kahn SR et al. Functional and exercise limitations after pulmonary embolism (ELOPE Study). Chest. 2017.